Retinopathy of prematurity (ROP) is the main cause of severe visual impairment and blindness in children. Based on the development of basic and clinical research, advancements have been made in the treatment of ROP. Other than high concentration oxygen supplement and oxidative stress, factors such as vascular endothelial growth factor (VEGF), placental growth factor (PGF), insulin-like growth factor-1 (IGF-1), and erythropoietin (EPO), have also been proven to play a key role in the pathogenesis of ROP. Moreover, benefited from basic study, anti-VEGF antibody therapy has been developed and widely applied, and the treatment of ROP do not need to only rely on cryoablation and laser photocoagulation. The above advances greatly inspired the confidence of the ROP's researchers. Overall, the progress of basic research has provided a solid theoretical basis for clinical prevention and treatment of ROP.
According to the latest data, the incidence of ROP still remains very high for low-birth-weight and premature infants. Undeniably, early diagnosis, prediction and prevention of ROP are still great challenges for pediatricians. Currently, solution of these challenges depends on the progress and deepening of basic research. Besides, we also need to open up new ideas to discover the deeper pathological mechanism of ROP.
This Research Topic aims to provide an academic platform for clinical and theoretical research on the regulation of ROP angiogenesis, and encourage more and more pediatricians and basic researchers to participate in the in-depth exploration of ROP.
Furthermore, this Research Topic is dedicated to presenting the latest developments of ROP research and clinical findings. Specifically, clinical and basic original articles, and reviews will be welcomed, including, but are not limited to, the following topics:
1. Innovative preventive measures for ROP in clinic.
2. Normalization of ocular development in very low birth weight infants and immature infants.
3. Retinal growth and development regulation, including non-coding RNAs, cytokines, signal transductive pathways.
4. Crucial pathogenic mechanism of ROP, including non-coding RNAs, cytokines, signal transductive pathways.
5. Innovative treatment methods for ROP, including anti-VEGF, or other anti-proangiogenic factor therapeutic methods.
6. Long-term effects of various treatments for ROP on the growth and development of children's eyes and various systems
7. Innovative examination and diagnosis techniques. It will provide more convenient, precise, economic, and efficient methods for ROP examination.
Retinopathy of prematurity (ROP) is the main cause of severe visual impairment and blindness in children. Based on the development of basic and clinical research, advancements have been made in the treatment of ROP. Other than high concentration oxygen supplement and oxidative stress, factors such as vascular endothelial growth factor (VEGF), placental growth factor (PGF), insulin-like growth factor-1 (IGF-1), and erythropoietin (EPO), have also been proven to play a key role in the pathogenesis of ROP. Moreover, benefited from basic study, anti-VEGF antibody therapy has been developed and widely applied, and the treatment of ROP do not need to only rely on cryoablation and laser photocoagulation. The above advances greatly inspired the confidence of the ROP's researchers. Overall, the progress of basic research has provided a solid theoretical basis for clinical prevention and treatment of ROP.
According to the latest data, the incidence of ROP still remains very high for low-birth-weight and premature infants. Undeniably, early diagnosis, prediction and prevention of ROP are still great challenges for pediatricians. Currently, solution of these challenges depends on the progress and deepening of basic research. Besides, we also need to open up new ideas to discover the deeper pathological mechanism of ROP.
This Research Topic aims to provide an academic platform for clinical and theoretical research on the regulation of ROP angiogenesis, and encourage more and more pediatricians and basic researchers to participate in the in-depth exploration of ROP.
Furthermore, this Research Topic is dedicated to presenting the latest developments of ROP research and clinical findings. Specifically, clinical and basic original articles, and reviews will be welcomed, including, but are not limited to, the following topics:
1. Innovative preventive measures for ROP in clinic.
2. Normalization of ocular development in very low birth weight infants and immature infants.
3. Retinal growth and development regulation, including non-coding RNAs, cytokines, signal transductive pathways.
4. Crucial pathogenic mechanism of ROP, including non-coding RNAs, cytokines, signal transductive pathways.
5. Innovative treatment methods for ROP, including anti-VEGF, or other anti-proangiogenic factor therapeutic methods.
6. Long-term effects of various treatments for ROP on the growth and development of children's eyes and various systems
7. Innovative examination and diagnosis techniques. It will provide more convenient, precise, economic, and efficient methods for ROP examination.
